The prognosis of malignant glioma is extremely poor, while various new approaches have been attempted (Catteral et al. 1980; Maruyama et al. 1982; Chang et al. 1983; Matsutani et al. 1984 ; Nelson et al. 1986 ; Keim et al. 1987 ; Deutsch et al. 1989; Hercbergs et al. 1989 ; Laramore et al. 1989 ; Shapiro et al. 1989 ; Goodman et al. 1990 ; Greiner et al. 1990 ; Brady et al. 1992) . Although the efficacy of radiotherapy for malignant glioma is proved by the improvement of survival rates (Sheline 1977; Walker et al. 1978) , tumor regression can be hardly seen. If repeated surgical treatment prolongs patients' survival, the effectuality of radiotherapy should be discussed. We investigated the radioresponse of malignant glioma by analyzing the change of contrast enhanced area (CEA) on CT scans to obtain relapse-free survival rate, which reflects the effectiveness of radiotherapy more directly.
MATERIALS AND METHODS
During the period from 1980 through 1990, one hundred and ten histopathologically diagnosed malignant gliomas were treated with irradiation at the Department of Radiology, Tohoku University School of Medicine in Japan. Of them, 91 patients were studied for this paper because the others were followed up insufficiently by CT scanning. There were 53 males and 38 females and average age was 50.9 years (range, 3-76 years). Fifty cases were diagnosed as astrocytoma grade III and 41 as glioblastoma.
We tried various radiation methods. Forty-four patients were treated with conventionally fractionated irradiation combined with chemotherapy using 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU,1 mg/kg) once a week. They received a total dose of 60 Gy. Thirty one patients underwent uneven fractionated irradiation : a radiation dose of 5 Gy combined with ACNU (1 mg/kg) on Monday followed by 1 Gy per fraction from Tuesday through Friday. A total dose of 54 Gy was delivered by this method. Eight patients received low dose rate telecobalt therapy (LDRT) as boost : a conventional radiation dose of 60 Gy followed by 14 Gy of the LDRT : 1 Gy/hr, 7 Gy/day. Eight patients were treated with 15 Gy of intraoperative irradiation (TORT) followed by 40 Gy of uneven fractionated irradiation combined with chemotherapy using ACN J (1 mg/kg). Twenty eight patients underwent curative resection (more than 95% removal), 28 partial resection and 35 only biopsy. Average period between surgery and radiation was 21.4 days (range, 4 to 46 days) in astrocytoma grade III and 24.1 days (range, 7 to 63 days) in glioblastoma.
Fifty-nine patients had definitive CEA in CT scans prior to irradiation, 18 minimal CEA, and 14 no CEA. Radioresponse of CEA was examined in 59 patients with the obvious CEA, and they were subdivided into the following five groups : complete response (CR), partial response (PR) (tumor regression of more than 50%), minor sponse (MR) (tumor regression of 30-50%), no changing (NC) and progressive disease (PD) group. A point of relapse was decided at the time when enlargement of CEA in CT scans was identified after radiotherapy. Regrowth was seen in 48 patients, and 29 of them were retreated with surgery, nine with radiation and 10 with none. General and relapse-free survival rates from the beginning of radiation were calculated by Kaplan-Meier method. In the calculation of relapse free survival rates, recurrent cases and cases where death occurred without relapse were computed as unsuccessful. A statistical comparison of survival rates was performed by Logrank test.
RESULTS

Local effect
There was no CR case, and tumor regression was observed only in 12 (20%) of 59 patients. No difference was seen in radioresponse between astrocytoma grade III and glioblastoma (Table 1) . Eight patients (42%) of uneven fractionation group and four patients (10%) of the other groups showed PR or MR regression ; uneven fractionated irradiation group exhibited a slightly improved regression rate than the others.
Relapsed site
Regrowth was observed in 48 patients, and 38 (79%) of them recurred within General survival rates were significantly higher than relapse free survival rates both in astrocytoma grade III cases and in glioblastoma cases (p <0.05). One-year, three-year and five-year relapse-free survival rates were 27.1%, 7.4%, 7.4% in conventionally fractionated group, 41.8%, 8.4%, 0% in uneven fractionated group, 25.0%, 12.5%, 0% in LDRT group and 37.5%, 0%, 0% in TORT group, respectively. There was no significant difference among them. Fig. 3 indicates the relapse free survival rates of astrocytoma grade III cases according to tumor status prior to the irradiation and radioresponse and Fig. 4 shows those of glioblastoma patients. The relapse free survival rate of CEA negative, PR or MR cases of astrocytoma grade III was higher than that of NC or PD cases, but the difference was insignificant. In glioblastoma the relapse free survival rate of CEA negative cases was significantly better than that of NC or PD cases (p <0.05).
The general survival rates of relapsed cases retreated with surgery or radiation were 65.8% at one year, 34.2% at two years and 18.4% at three years, while those of relapsed cases without retreatment 30.0% at one year and 0% at two years, and (n=41). Fig . 3 . Relapse free survival rates of astrocytoma grade III patients by radioresponse.
CEA(-) (n=13); ---, PR+MR (n=6); ------, NC+PD (n=25)
. CEA (-), contrast enhanced area negative in CT scans prior to irradiation ; PR, partial response (more than 50% regression) ; MR, minor response (less than 50% regression), NC, no changing ; PD, progressive disease. CEA (-) (n=13) ; ---, PR+MR (n=6) ; ------, NC+PD (n=25). CEA (-), contrast enhanced area negative in CT scans prior to irradiation ; PR, partial response (more than 50% regreession) ; MR, minor response (less than 50% regression),NC, no changing ; PD, progressive disease. these difference was significant (p <0.01).
Brain necrosis
Brain necrosis which was identified by CT scans as an enlargement of low density area was observed in ten patients and Fig. 5 shows the actuarial rate of brain necrosis. It was 18.0% at one year and 37.6% at three years. , have been attempted for malignant glioma, all failed to improve the patients' survival. We also applied different radiation methods ; uneven fractionated irradiation combined with ACNIJ (Mashiyama et al. 1989 ), LDRT as boost (Yamada et al. 1992) , and TORT (Matsutani et al. 1984 ) followed by uneven fractionated irradiation. All of our methods did not reform the patients' prognosis because radioresponse of malignant glioma is extremely poor. There was no CR in our patients. Sheline (1977) and Walker et al. (1978) reported the advantage of post-operative irradiation over the surgical treatment alone. However, if repeated surgical treatment prolonged patients' survival, the efficacy of radiation therapy should be reexamined. To discuss the effectiveness of radiotherapy, relapse free survival rate is alternative because retreatment may not be delivered before relapse. In our cases general survival rates were significantly higher than relapse free survival rates both in astrocytoma grade III and in glioblastoma. This means that retreatment after relapse is quite important, and the survival of relapsed cases with retreatment was significantly higher than that of the other relapsed cases. Sheline (1977) showed the survival rate of astrocytoma grade III treated with resection alone was 12% at one year, and 6% at two years. Where we observed relapse free survival rate of our astrocytoma grade III cases of 46% at one year, and 23% at two years. Sheline (1977) also reported survival rates for glioblastoma to be 8% at one year, and 3% at two years. We observed 18% at one year and 3% at two years. The efficiency of radiation is most remarkable in astrocytoma grade III. Further, in astrocytoma grade III one year and two year relapse free survival rates were 62%, 28% in CEA negative cases and 34%, 20% in NC or PD cases, respectively. On the other hand in glioblastoma one year and two year relapse free survival rates were 39%, 0% in CEA negative cases and 5%, 0% in NC or PD cases, respectively. The effectiveness of radiotherapy for malignant glioma is clear in astrocytoma grade III and a part of glioblastoma ; cases with minimal or no CEA in CT scans prior to irradiation. To NC or PD cases of glioblastoma, reoperation should not be hesitated if possible.
Almost all relapsed tumors recurred within initial radiation field because 79% recurred within 2 cm from the margin of primary tumor as Wallner et al. (1989) mentioned and brain necrosis was observed 37.6% of patients at three years. Technical improvement of irradiation against malignant glioma appears to be little advantage and radiation dose seems maximum for safety level. Some radiosensitizers should be developed.
In conclusion, the retreatment after relapse is quite important for malignant glioma. In comparison with reported resection alone data, the, effectiveness of radiotherapy was remarkable in astrocytoma grade III and a part of glioblastoma, cases with minimal or no CEA prior to irradiation. 
